Pulmicort

Teva Pharmaceutical (NASDAQ: TEVA) on Thursday released its 2015 outlook. Here are some of the business-related highlights: Foreign exchange rates are expected to have a $700 million adverse impact on revenues. Copaxone 20 mg/mL is expected to face two AB-rated generic competitors in the...